SIGHT
vs
D
DAX Index
SIGHT
Over the past 12 months, SIGHT has underperformed DAX Index, delivering a return of -74% compared to the DAX Index's +12% growth.
Stocks Performance
SIGHT vs DAX Index
Performance Gap
SIGHT vs DAX Index
Performance By Year
SIGHT vs DAX Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Gensight Biologics SA
Glance View
GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).